ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LENZ LENZ Therapeutics Inc

18.54
-0.09 (-0.48%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 127,008
Bid Price 17.86
Ask Price 19.00
News -
Day High 19.48

Low
14.42

52 Week Range

High
24.59

Day Low 17.89
Share Name Share Symbol Market Stock Type
LENZ Therapeutics Inc LENZ NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.09 -0.48% 18.54 23:00:16
Open Price Low Price High Price Close Price Previous Close
17.89 17.89 19.48 18.54 18.63
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
4,047 127,008 US$ 18.51 US$ 2,351,537 - 14.42 - 24.59
Last Trade Type Quantity Price Currency
16:31:14 71 US$ 18.00 USD

LENZ Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
474.17M 25.53M - 0 -124.65M -4.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

LENZ Therapeutics News

Date Time Source News Article
6/10/202407:00GlobeNewswire Inc.LENZ Therapeutics to Host Key Opinion Leader Event on June..
5/30/202407:00GlobeNewswire Inc.LENZ Therapeutics to Present at the Jefferies Global..
5/21/202407:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
5/09/202415:18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
5/08/202416:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/08/202415:05Edgar (US Regulatory)Form 8-K - Current report
5/08/202415:01GlobeNewswire Inc.LENZ Therapeutics Reports First Quarter 2024 Financial..
5/01/202415:01GlobeNewswire Inc.LENZ Therapeutics to Report First Quarter Financial Results..
4/03/202406:00Business WireLENZ Therapeutics Announces Positive Topline Data from Phase..
4/02/202415:01Business WireLENZ Therapeutics to Host Investor Call to Discuss Topline..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LENZ Message Board. Create One! See More Posts on LENZ Message Board See More Message Board Posts

Historical LENZ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week15.0419.9814.920118.20180,8063.5023.27%
1 Month16.5019.9814.4216.63180,9372.0412.36%
3 Months15.9824.5914.4217.23159,9032.5616.02%
6 Months15.9824.5914.4217.23159,9032.5616.02%
1 Year15.9824.5914.4217.23159,9032.5616.02%
3 Years15.9824.5914.4217.23159,9032.5616.02%
5 Years15.9824.5914.4217.23159,9032.5616.02%

LENZ Therapeutics Description

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.

Your Recent History

Delayed Upgrade Clock